Summarized by Masters of Longevity from BioAge Labs.
Company leaders will present clinical progress and upcoming data readouts.
Key Takeaways
- BioAge is presenting clinical progress and near-term data readouts.
- BGE-102 showed tolerability and reduced hsCRP in Phase 1.
- QUELL-CV Phase 2 cardiovascular data are expected in Q4 2026.
